CGTX

+ Watchlist + Portfolio

Cognition Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.98
52-Week Range: $0.55 – $3.83
Market Cap: $90.98M
P/E (TTM): —
EPS (TTM): -0.17
Dividend Yield: —

Advanced Metrics

Price/Book: 2.76
PEG Ratio: —
Return on Equity: -83.76%
Return on Assets: -78.18%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 7.03
Debt/Equity: 0.02
Total Debt: $589.00K
Free Cash Flow: $-23.95M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $59.65M

CGTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$30.32M	$37.20M	$41.68M	$37.19M
Selling, General & Admin	$13.23M	$13.53M	$12.29M	$10.61M
Operating Expenses	$21.33M	$25.92M	$34.42M	$24.39M
Operating Income	-$21.33M	-$25.92M	-$34.42M	-$24.39M
EBITDA	-$21.13M	-$25.51M	-$33.68M	-$23.25M
Pretax Income	-$21.40M	-$25.79M	-$33.97M	-$23.49M
Net Income	-$21.40M	-$25.79M	-$33.97M	-$23.49M
Diluted EPS	-0.91	-0.86	-0.86	-0.32
Diluted Shares	23.64M	30.03M	39.73M	72.77M

CGTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$41.56M	$29.92M	$25.01M	$36.81M
Receivables	$3.67M	$1.28M	$2.69M	$9.92M
Current Assets	$47.65M	$34.22M	$29.55M	$47.99M
Total Assets	$50.42M	$35.16M	$30.23M	$48.39M
Current Liabilities	$7.79M	$10.17M	$11.14M	$13.92M
Total Debt	$1.48M	$1.24M	$814.00K	$638.00K
Total Liabilities	$10.18M	$10.69M	$11.48M	$14.12M
Retained Earnings	-$115.40M	-$141.19M	-$175.16M	-$198.65M
Shareholders' Equity	$40.25M	$24.47M	$18.75M	$34.27M
Working Capital	$39.85M	$24.05M	$18.41M	$34.07M

CGTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.53M	-$16.02M	-$28.47M	-$24.59M
Capital Expenditure	-$171.00K	-$147.00K	-$4.00K	—
Free Cash Flow	-$18.70M	-$16.16M	-$28.48M	-$24.59M
Depreciation & Amortisation	$235.00K	$252.00K	$266.00K	$228.00K
Stock-Based Compensation	$3.57M	$4.35M	$3.75M	$2.09M
Investing Cash Flow	-$171.00K	-$147.00K	-$4.00K	$9.00K
Financing Cash Flow	$5.55M	$4.52M	$23.57M	$36.57M
Net Change in Cash	-$13.16M	-$11.64M	-$4.91M	$11.99M

CGTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.79M	$11.48M	$3.77M	$11.15M	$6.12M
Selling, General & Admin	$2.99M	$2.50M	$2.60M	$2.52M	$2.70M
Operating Expenses	$8.69M	$6.87M	$5.16M	$3.67M	$4.84M
Operating Income	-$8.69M	-$6.87M	-$5.16M	-$3.67M	-$4.84M
EBITDA	-$8.43M	-$6.67M	-$4.87M	-$3.28M	-$4.50M
Pretax Income	-$8.48M	-$6.73M	-$4.93M	-$3.34M	-$4.57M
Net Income	-$8.48M	-$6.73M	-$4.93M	-$3.34M	-$4.57M
Diluted EPS	-0.14	-0.11	-0.06	—	-0.05
Diluted Shares	61.83M	63.69M	77.95M	—	89.19M

CGTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$16.43M	$10.74M	$39.33M	$36.81M	$31.13M
Receivables	$4.78M	$6.29M	$1.90M	$9.92M	$3.66M
Current Assets	$22.87M	$19.05M	$42.88M	$47.99M	$35.81M
Total Assets	$23.50M	$19.62M	$43.40M	$48.39M	$36.14M
Current Liabilities	$10.95M	$12.36M	$6.65M	$13.92M	$6.05M
Total Debt	$635.00K	$468.00K	$380.00K	$638.00K	$465.00K
Total Liabilities	$11.23M	$12.59M	$6.87M	$14.12M	$6.23M
Retained Earnings	-$183.64M	-$190.37M	-$195.30M	-$198.65M	-$203.22M
Shareholders' Equity	$12.27M	$7.03M	$36.53M	$34.27M	$29.91M
Working Capital	$11.92M	$6.68M	$36.23M	$34.07M	$29.76M

CGTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.88M	-$5.62M	-$5.65M	-$3.44M	-$5.54M
Free Cash Flow	-$9.88M	-$5.62M	-$5.65M	-$3.44M	-$5.54M
Depreciation & Amortisation	$45.00K	$61.00K	$61.00K	$61.00K	$68.00K
Stock-Based Compensation	$586.00K	$621.00K	$522.00K	$358.00K	$330.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$9.00K	$0.00
Financing Cash Flow	$1.30M	$752.00K	$33.92M	$605.00K	-$233.00K
Net Change in Cash	-$8.58M	-$4.87M	$28.27M	-$2.82M	-$5.78M

Market Snapshot

About

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's disease and other neurodegenerative disorders. The company's lead product candidate targets the underlying mechanisms of neurodegeneration rather than just treating symptoms. Cognition Therapeutics focuses on addressing the toxic oligomer hypothesis of Alzheimer's disease through its proprietary drug platform. The company conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates in patients with mild-to-moderate Alzheimer's disease. Cognition Therapeutics collaborates with academic institutions and research organizations to advance its understanding of neurodegenerative processes. The company's research pipeline includes multiple programs aimed at addressing significant unmet medical needs in neurological conditions affecting millions of patients worldwide.